Tyrosine kinase inhibitors (TKI’s) targeting FLT3 have been approved for the treatment of various solid tumors (e.g., sorafenib for renal cell carcinoma (RCC), hepatocellular carcinoma and thyroid cancer, sunitinib for RCC and gastrointestinal tumors) but their role in the treatment of AML has not been established [19,20]. The gene discussed is FLT3; the disease is renal cell carcinoma.